The popularity of weight-loss drugs like Novo Nordisk's (NVO) Wegovy has raised concerns for investors in the food and beverage industry. Anheuser-Busch InBev (BUD) CEO Michel Doukeris tells Yahoo Finance Executive Editor Brian Sozzi that he thinks beer is immune to consumers' changing preferences as weight-loss drugs become more popular.

"If you look at the research and you look at the profile of these users and how they interact with beverages, it's fair to say that beer is a little bit separated. Why? It is still part of consumption, but because we are not in the sweet part of the industry," like wine and cocktails, AB InBev is less impacted by the weight-loss push, Doukeris explains.

The chief executive highlights AB InBev's lower calorie, lower carb, and non-alcoholic options, which also help appeal to those looking to maintain a balanced diet, saying, "In a way, beer fits well for this type of occasion."

To see every interview from Yahoo Finance Invest, click here. Watch the full interview with Michel Doukeris by clicking here.

This post was written by Naomi Buchanan.